Because of advances in linker conjugation chemistry and our understanding of the ADC mechanism of action in vivo, an increasing breadth of anticancer agents are now being incorporated in newer ADC ...
Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results